Biliary Tract Cancer

Common Name(s)

Biliary Tract Cancer

Bile Tract Cancer is a rare digestive cancer characterized by abnormal cell growth in the bile ducts and gallbladder. Individuals with this disorder may grow harmful tumors that can spread to the rest of the body if not diagnosed early. The bile duct system is responsible for storing and transporting bile from the liver, where it is made, to the intestines, where it helps to digest food. Incomplete development of the ducts inhibits the flow of bile. Individuals with this defect have digestion problems as well as a yellow discoloration of the eye and skin (jaundice). Doctors are usually able to diagnose this defect early in the abnormal growth process, as the resulting symptoms are quickly apparent. Treatment is developed on a case-by-case basis and depends on the specific needs of the patient. For prevention measures, digestion specialists may suggest individuals eat a lower-fat diet, or undergo surgery to relieve the blockage or create a tube to allow bile to reach the digestive system. If an individual's cancer has progressed, doctors may suggest chemotherapy to combat cancer symptoms.

Source: Advocacy organizations associated with the condition.

 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Biliary Tract Cancer" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Biliary Tract Cancer" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Biliary Tract Cancer" returned 149 free, full-text research articles on human participants. First 3 results:

Early Gastric Cancer Recurrence Following Curative Resection Presenting as Biliary Tract Dilatation, Pancreatic Duct Dilatation and Intestinal Wall Thickening.
 

Author(s): Hiroyuki Kato, Yukiko Ito, Eri Tanaka, Kensaku Noguchi, Shinzo Yamamoto, Hiroyoshi Taniguchi, Hideo Yoshida, Toshio Kumasaka, Ryo Nakata

Journal: Intern. Med.. 2016 ;55(7):745-50.

 

Early gastric cancer, especially cancer confined to the mucosa (stage T1a), is known to have a high cure rate with rare recurrence. We herein report the case of a 40-year-old female who initially presented with biliary tract dilatation, pancreatic duct dilatation and intestinal wall ...

Last Updated: 4 Apr 2016

Go To URL
Correlations of survival with progression-free survival, response rate, and disease control rate in advanced biliary tract cancer: a meta-analysis of randomised trials of first-line chemotherapy.
 

Author(s): Toshikazu Moriwaki, Yoshiyuki Yamamoto, Masahiko Gosho, Mariko Kobayashi, Akinori Sugaya, Takeshi Yamada, Shinji Endo, Ichinosuke Hyodo

Journal: Br. J. Cancer. 2016 Apr;114(8):881-8.

 

The need to promote novel drug development for advanced biliary tract cancer (ABTC) has emphasised the importance of determining whether various efficacy end points can act as surrogates for overall survival (OS).

Last Updated: 13 Apr 2016

Go To URL
Randomized Phase III study of gemcitabine plus S-1 versus gemcitabine plus cisplatin in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1113, FUGA-BT).
 

Author(s): Junki Mizusawa, Chigusa Morizane, Takuji Okusaka, Hiroshi Katayama, Hiroshi Ishii, Haruhiko Fukuda, Junji Furuse,

Journal: Jpn. J. Clin. Oncol.. 2016 Apr;46(4):385-8.

 

A Phase II selection design trial was conducted to identify the most promising regimen for comparison with standard therapy in chemo-naive patients with unresectable or recurrent biliary tract cancer (JCOG0805). Gemcitabine plus S-1 therapy showed better efficacy than S-1 monotherapy ...

Last Updated: 30 Mar 2016

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Biliary Tract Cancer" returned 9 free, full-text review articles on human participants. First 3 results:

Optimum chemotherapy for the management of advanced biliary tract cancer.
 

Author(s): Marwan Ghosn, Hampig Raphael Kourie, Elie El Rassy, Ralph Chebib, Fadi El Karak, Colette Hanna, Dolly Nasr

Journal: World J. Gastroenterol.. 2015 Apr;21(14):4121-5.

 

Biliary tract cancers (BTCs) are highly fatal malignancies, which are often diagnosed at an advanced stage and have relatively poor prognosis. The treatment of patients with advanced BTC is systemic, based on chemotherapy or best supportive care, depending on their performance status. ...

Last Updated: 20 Apr 2015

Go To URL
Efficacy and safety of gemcitabine-based chemotherapies in biliary tract cancer: a meta-analysis.
 

Author(s): Heng Liu, Qi-Di Zhang, Zheng-Hong Li, Qing-Qing Zhang, Lun-Gen Lu

Journal: World J. Gastroenterol.. 2014 Dec;20(47):18001-12.

 

To investigate the efficacy and safety of gemcitabine (Gem)-based combination chemotherapies for the treatment of advanced biliary tract cancer.

Last Updated: 30 Dec 2014

Go To URL
Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review.
 

Author(s): Frédéric Fiteni, Thierry Nguyen, Dewi Vernerey, Marie-Justine Paillard, Stefano Kim, Martin Demarchi, Francine Fein, Christophe Borg, Franck Bonnetain, Xavier Pivot

Journal: Cancer Med. 2014 Dec;3(6):1502-11.

 

Cisplatin/gemcitabine association has been a standard of care for first-line regimen in advanced biliary tract cancer nevertheless oxaliplatin/gemcitabine regimen is frequently preferred. Because comparative effectiveness in clinical outcomes of cisplatin- versus oxaliplatin-containing ...

Last Updated: 5 Jan 2015

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in Genetics Home Reference.

There are currently no related results available in GeneReviews.

There are currently no related results available in Genetic Testing Registry.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

MEK162 in Combination With Capecitabine in Advanced Biliary Tract Cancer
 

Status: Recruiting

Condition Summary: Biliary Tract Cancer

 

Last Updated: 15 May 2016

Go to URL

Last Updated: 18 Aug 2016

Go to URL
A Phase II Trial of Preoperative Chemotherapy for Biliary Tract Cancer (BTC) With Node Metastasis
 

Status: Recruiting

Condition Summary: Biliary Tract Cancer

 

Last Updated: 31 Aug 2016

Go to URL